Putative role of hif transcriptional activity in melanocytes and melanoma biology

Dermato-Endocrinology

Volumn 5, Issue 2, 2013, Pages 239-251

  Zbytek, Blazej ^a   Peacock, Danielle L ^a   Seagroves, Tiffany N ^a   Slominski, Andrzej ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hif 1; Keratinocytes; Melanocytes; Melanoma; Oncogenesis; Skin

Indexed keywords

AFP 464; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; DACARBAZINE; DACINOSTAT; DIGOXIN; ENZ 2968; FLAVONE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IPILIMUMAB; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OLIGONUCLEOTIDE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; TANESPIMYCIN; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VEMURAFENIB;

APOPTOSIS; BIOINFORMATICS; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CELL FUNCTION; CRH GENE; DNA REPAIR; DNA RESPONSIVE ELEMENT; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; HYPOXIA RESPONSIVE ELEMENT; ISOLATE LIMB PERFUSION; KERATINOCYTE; KIDNEY CANCER; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA CELL; NEVUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; ONCOGENE H RAS; OVERALL SURVIVAL; PMEL GENE; REVIEW; SLC45A2 GENE; TRPM1 GENE; ULTRAVIOLET B RADIATION;

EID: 84885127137     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.22678     Document Type: Review

References (157)

1. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 2007:cm8; PMID:17925579; http://dx.doi.org/10.1126/stke.4072007cm8.
2. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif )-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63:6130-4; PMID:14559790.
3. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 2011; 117:e207-17; PMID:21447827; http://dx.doi. org/10.1182/blood-2010-10- 314427.
4. Hu J, Stiehl DP, Setzer C, Wichmann D, Shinde DA, Rehrauer H, et al. Interaction of HIF and USF signaling pathways in human genes flanked by hypoxiaresponse elements and E-box palindromes. Mol Cancer Res 2011; 9:1520-36; PMID:21984181; http://dx.doi. org/10.1158/1541-7786.MCR-11-0090.
5. Stiehl DP, Bordoli MR, Abreu-Rodriguez I, Wollenick K, Schraml P, Gradin K, et al. Non-canonical HIF-2 function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene 2012; 31:2283-97; PMID:21927022; http://dx.doi. org/10.1038/onc.2011.417.
6. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425:307-11; PMID:13679920; http:// dx.doi.org/10.1038/nature01874.
7. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997; 272:20055-62; PMID:9242677; http://dx.doi. org/10.1074/jbc.272.32.20055.
8. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291:F271-81; PMID:16554418;.
9. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996; 16:4604-13; PMID:8756616.
10. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222- 6; PMID:16642001; http://dx.doi.org/10.1038/ nature04695.
11. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxiainducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5; PMID:10582706.
12. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12:853- 9; PMID:17933687;.
13. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol 2012; 212:v, vii, 1-115; PMID:22894052.
14. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000; 21:457-87; PMID:11041445;.
15. Fitzpatrick TBEA, Wolff K, Freedberg IM, Austen KF. Dermatology in General Medicine. New York: McGraw Hill, 1993.
16. Evans SM, Schrlau AE, Chalian AA, Zhang P, Koch CJ. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Dermatol 2006; 126:2596-606; PMID:16810299; http://dx.doi.org/10.1038/sj.jid. 5700451. 17. Bedogni B, Powell MB. Skin hypoxia: a promoting environmental factor in melanomagenesis. Cell Cycle 2006; 5:1258-61; PMID:16760649; http://dx.doi. org/10.4161/cc.5.12.2810.
17. Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 2008; 133:223-34; PMID:18423195; http://dx.doi. org/10.1016/j.cell.2008.02.038.
18. Taichman LB, Setlow RB. Repair of ultraviolet light damage to the DNA of cultured human epidermal keratinocytes and fibroblasts. J Invest Dermatol 1979; 73:217-9; PMID:469274; http://dx.doi. org/10.1111/1523-1747.ep12514242.
19. de Gruijl FR. p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects. Exp Dermatol 2002; 11(Suppl 1):37-9; PMID:12444958; http://dx.doi.org/10.1034/j.1600-0625.11.s.1.9.x.
20. Chaturvedi V, Sitailo LA, Qin JZ, Bodner B, Denning MF, Curry J, et al. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis. Oncogene 2005; 24:5299-312; PMID:15940268; http://dx.doi.org/10.1038/sj.onc.1208650.
21. Cho YS, Bae JM, Chun YS, Chung JH, Jeon YK, Kim IS, et al. HIF-1alpha controls keratinocyte proliferation by up-regulating p21(WAF1/Cip1). Biochim Biophys Acta 2008; 1783:323-33; PMID:18166158; http:// dx.doi.org/10.1016/j. bbamcr.2007.11.017.
22. Nys K, Maes H, Dudek AM, Agostinis P. Uncovering the role of hypoxia inducible factor-1 in skin carcinogenesis. Biochim Biophys Acta 2011; 1816:1-12; PMID:21338656.
23. Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Stenvold H, Busund LT, et al. Correlation and coexpression of HIFs and NOTCH markers in NSCLC. Anticancer Res 2011; 31:1603-6; PMID:21617216.
24. Raza S, Kornblum N, Kancharla VP, Baig MA, Singh AB, Kalavar M. Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. Recent Pat Anticancer Drug Discov 2011; 6:246-57; PMID:21247406; http://dx.doi. org/10.2174/157489211795328477.
25. Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys 2011; 79:325-34; PMID:21195874; http://dx.doi.org/10.1016/j.ijrobp.2010.09.043.
26. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, et al. Elevated expression of thymosin ?4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1? in early-stage cervical cancers. Pathol Oncol Res 2011; 17:493-502; PMID:21213129; http://dx.doi.org/10.1007/s12253-010-9327-x.
27. Strieth S, Hartschuh W, Pilz L, Fusenig NE. Angiogenic switch occurs late in squamous cell carcinomas of human skin. Br J Cancer 2000; 82:591-600; PMID:10682671; http://dx.doi.org/10.1054/ bjoc.1999.0969.
28. Scortegagna M, Martin RJ, Kladney RD, Neumann RG, Arbeit JM. Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res 2009; 69:2638-46; PMID:19276359; http://dx.doi. org/10.1158/0008-5472.CAN-08-3643.
29. Mackenzie KA, Miller AP, Hock BD, Gardner J, Simcock JW, Roake JA, et al. Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology 2011; 58:875-85; PMID:21585427; http://dx.doi.org/10.1111/j.1365-2559.2011.03845.x.
30. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004; 84:1155-228; PMID:15383650; http://dx.doi.org/10.1152/physrev. 00044.2003.
31. Wood JM, Jimbow K, Boissy RE, Slominski A, Plonka PM, Slawinski J, et al. What's the use of generating melanin? Exp Dermatol 1999; 8:153-64; PMID:10232409; http://dx.doi.org/10.1111/j.1600-0625.1 99. tb00365.x.
32. Slominski A, Paus R, Schadendorf D. Melanocytes as "sensory"and regulatory cells in the epidermis. J Theor Biol 1993; 164:103-20; PMID:8264240; http:// dx.doi.org/10.1006/jtbi.1993.1142.
33. Slominski A. Neuroendocrine activity of the melanocyte. Exp Dermatol 2009; 18:760-3; PMID:19558501; http://dx.doi.org/10.1111/j.1600-0625.2009.00892. x.
34. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol 1993; 101(Suppl):90S-7S; PMID:8326158; http://dx.doi.org/10.1111/1523-1747.ep12362991.
35. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. J Invest Dermatol 2005; 124:13-21; PMID:15654948; http://dx.doi.org/10.1111/j.0022-202X.2004.23528.x.
36. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L- dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 2012; 25:14-27; PMID:21834848; http://dx.doi. org/10.1111/j.1755-148X.2011.00898.x.
37. Slominski A, Paus R. Are L-tyrosine and L-dopa hormone-like bioregulators? J Theor Biol 1990; 143:123-38; PMID:2359315; http://dx.doi.org/ 10.1016/ S0022-5193(05)80292-9.
38. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010; 46:1159-69; PMID:20185296; http://dx.doi.org/10.1016/j.ejca.2010.01.031.
39. Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, et al. Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 2009; 34:e962-4; PMID:20055873; http://dx.doi. org/10.1111/j.1365-2230.2009.03706.x.
40. Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer 2009; 8:104; PMID:19919690; http://dx.doi. org/10.1186/1476-4598-8-104.
41. Trevino-Villarreal JH, Cotanche DA, Sepulveda R, Bortoni ME, Manneberg O, Udagawa T, et al. Host-derived pericytes and Sca-1+ cells predominate in the MART-1-stroma fraction of experimentally induced melanoma. J Histochem Cytochem 2011; 59:1060-75; PMID:22147606; http://dx.doi. org/10.1369/0022155411428078.
42. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13:493-501; PMID:14512791; http://dx.doi.org/10.1097/00008390-200310000-00008.
43. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr., Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008; 3:569-85; PMID:19649148; http://dx.doi. org/10.1586/17469872.3.5.569.
44. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges 2012; 10:319-25; PMID:22432863; http://dx.doi. org/10.1111/j.1610-0387.2012.07895.x.
45. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; CD001215; PMID:10796759.
46. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/ S0140-6736(12)60868-X.
47. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012; 132:854-63; PMID:22217739; http:// dx.doi.org/10.1038/jid.2011.421.
48. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 2009; 124:1470-7; PMID:19085934; http://dx.doi. org/10.1002/ijc.24005.
49. Slominski A, Paus R, Mihm MC. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res 1998; 18(5B):3709-15; PMID:9854482.
50. Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab with Alternative Therapies in the Management of Pretreated Patients with Unresectable Stage III or IV Melanoma. Oncologist 2012; PMID:23024154; http://dx.doi.org/10.1634/theoncologist. 2011-0427.
51. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994; 220:520-34, discussion 534-5; PMID:7944662; http:// dx.doi.org/10.1097/00000658- 199410000-00010.
52. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007; 249:188-97; PMID:16997457; http://dx.doi.org/10.1016/j.canlet. 2006.08.016.
53. Jing Y, Ma N, Fan T, Wang C, Bu X, Jiang G, et al. Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. Cancer Invest 2011; 29:485-93; PMID:21740086.
54. Pourahmad J, Amirmostofian M, Kobarfard F, Shahraki J. Biological reactive intermediates that mediate dacarbazine cytotoxicity. Cancer Chemother Pharmacol 2009; 65:89-96; PMID:19399501; http://dx.doi. org/10.1007/s00280-009- 1007-8.
55. Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, et al. HIF-1? stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 2011; 51:893-904; PMID:21703345; http://dx.doi.org/10.1016/j.freeradbiomed. 2011.05.042.
56. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883-5; PMID:12873977.
57. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007; 67:3177-84; PMID:17409425;
58. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33:207-14; PMID:22398146; http://dx.doi.org/10.1016/j.tips.2012.01.005.
59. Yang XC, Tu CX, Luo PH, Zhu H, Zhu DF, Wu HH, et al. Antimetastatic activity of MONCPT in preclinical melanoma mice model. Invest New Drugs 2010; 28:800-11; PMID:19789842; http://dx.doi. org/10.1007/s10637-009-9323-8.
60. Paradziej-?ukowicz J, Skwarska A, Peszy?ska-Sularz G, Brillowska-D?browska A, Konopa J. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1? (HIF-1?), vascular endothelial growth factor (VEGF) and angiogenesis. Cancer Biol Ther 2011; 12:586-97; PMID:21775820; http://dx.doi. org/10.4161/cbt.12.7.15980.
61. de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 2012; 31:1105-16; PMID:21765463; http://dx.doi. org/10.1038/onc.2011.309.
62. Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, et al. Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 2009; 17:269-77; PMID:19066596; http://dx.doi.org/10.1038/ mt.2008.266.
63. Jones DT, Harris AL. Identification of novel smallmolecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 2006; 5:2193-202; PMID:16985052; http://dx.doi. org/10.1158/1535-7163.MCT-05- 0443.
64. Coleman C, Levine D, Kishore R, Qin G, Thorne T, Lambers E, et al. Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides. J Oncol 2010; 2010:928628; PMID:20652008; http://dx.doi. org/10.1155/2010/928628.
65. Pratheeshkumar P, Kuttan G. Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1?, MMP-2, MMP-9, and VEGF. J Environ Pathol Toxicol Oncol 2011; 30:139-51; PMID:21967458; http://dx.doi.org/10.1615/ JEnvironPatholToxicolOncol.v30.i2.50.
66. Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol 2012; 35:57-70; PMID:22145808; http://dx.doi.org/10.3109/0148054 5.2011.589437.
67. Song H, Kim J, Lee HK, Park HJ, Nam J, Park GB, et al. Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression. Int Immunopharmacol 2011; 11:2208-13; PMID:22008306; http://dx.doi.org/10.1016/j. intimp.2011.10.002.
68. Shah M, Stebbins JL, Dewing A, Qi J, Pellecchia M, Ronai ZA. Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res 2009; 22:799-808; PMID:19712206; http://dx.doi.org/10.1111/j.1755-148X.2009.00628.x.
69. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77:78-86; PMID:18805433; http://dx.doi.org/10. 1016/j. mvr.2008.08.003.
70. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 2011; 105:231-8; PMID:21673687; http://dx.doi. org/10.1038/bjc.2011. 226.
71. Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca T, Ziparo E, et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ 2011; 18:1024-35; PMID:21233846; http:// dx.doi.org/10.1038/cdd.2010.175.
72. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HS 90. PLoS ONE 2010; 5:e11772; PMID:20668552; http://dx.doi. org/10.1371/journal.pone.0011772.
73. Coma S, Shimizu A, Klagsbrun M. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F-and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adh Migr 2011; 5:266-75; PMID:21610314; http:// dx.doi.org/10.4161/cam.5.3.16294.
74. Pelletier J, Dayan F, Durivault J, Ilc K, Pecou E, Pouyssegur J, et al. The asparaginyl hydroxylase factorinhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis. Oncogene 2012; 31:2989-3001; PMID:22002313; http://dx.doi. org/10.1038/onc.2011.471.
75. Plonka PM, Passeron T, Brenner M, Tobin DJ, Shibahara S, Thomas A, et al. What are melanocytes really doing all day long...? Exp Dermatol 2009; 18:799-819; PMID:19659579; http://dx.doi. org/10.1111/j.1600-0625.2009.00912.x.
76. Hearing VJ. Biochemical control of melanogenesis and melanosomal organization. J Investig Dermatol Symp Proc 1999; 4:24-8; PMID:10537003; http://dx.doi. org/10.1038/sj.jidsp.5640176.
77. Schallreuter KU, Kothari S, Chavan B, Spencer JD. Regulation of melanogenesis-controversies and new concepts. Exp Dermatol 2008; 17:395-404; PMID:18177348; http://dx.doi.org/10.1111/j.1600-0625.2007.00675.x.
78. Slominski A, Paus R. Towards defining receptors for L-tyrosine and L-dopa. Mol Cell Endocrinol 1994; 99:C7-11; PMID:8206317; http://dx.doi. org/10.1016/0303-7207(94)90001-9.
79. Slominski A, Moellmann G, Kuklinska E. L-tyrosine, L-dopa, and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in Bomirski Ab amelanotic melanoma cells. Pigment Cell Res 1989; 2:109-16; PMID:2497448; http://dx.doi. org/10.1111/j.1600-0749.1989.tb00170.x.
80. Scis?owski PW, S?omi?ski A, Bomirski A. Biochemical characterization of three hamster melanoma variants-II. Glycolysis and oxygen consumption. Int J Biochem 1984; 16:327-31; PMID:6698297; http://dx.doi. org/10.1016/0020-711X(84) 90107-1.
81. Scis?owski PW, S?ominski A. The role of NADPdependent dehydrogenases in hydroxylation of tyrosine in hamster melanoma. Neoplasma 1983; 30:239-43; PMID:6405289.
82. Scis?owski PW, S?omi?ski A, Bomirski A, Zydowo M. Metabolic characterization of three hamster melanoma variants. Neoplasma 1985; 32:593-8; PMID:4069292.
83. Li W, Slominski R, Slominski AT. High-resolution magic angle spinning nuclear magnetic resonance analysis of metabolic changes in melanoma cells after induction of melanogenesis. Anal Biochem 2009; 386:282-4; PMID:19138655; http://dx.doi. org/10.1016/j.ab.2008.12.017.
84. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000; 80:979-1020; PMID:10893429.
85. Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J 2001; 15:1678-93; PMID:11481215; http://dx.doi.org/10.1096/fj.00-0850rev.
86. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 2005; 162:97-102; PMID:15833364; http://dx.doi.org/10.1016/j. jneuroim.2005.01.014.
87. Slominski A, Zbytek B, Szczesniewski A, Semak I, Kaminski J, Sweatman T, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab 2005; 288:E701-6; PMID:15572653; http://dx.doi. org/10.1152/ajpendo.00519.2004.
88. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, et al. Corticotropin releasing hormone and the skin. Front Biosci 2006; 11:2230-48; PMID:16720310; http://dx.doi.org/10.2741/1966.
89. Nakayama K, Fukamachi S, Kimura H, Koda Y, Soemantri A, Ishida T. Distinctive distribution of AIM1 polymorphism among major human populations with different skin color. J Hum Genet 2002; 47:92-4; PMID:11916009; http://dx.doi.org/10.1007/ s100380200007.
90. Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, et al. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 2001; 69:981-8; PMID:11574907; http://dx.doi.org/10.1086/324340.
91. Kwon BS, Halaban R, Ponnazhagan S, Kim K, Chintamaneni C, Bennett D, et al. Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. Nucleic Acids Res 1995; 23:154-8; PMID:7870580; http://dx.doi. org/10.1093/nar/23.1.154.
92. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998; 58:1515-20; PMID:9537257.
93. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, et al. In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 1991; 10:2111-8; PMID:1712289.
94. Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, et al. Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012; PMID:22618666; http:// dx.doi.org/10.1007/s12032-012-0255-3.
95. Du J, Fisher DE. Identification of Aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF. J Biol Chem 2002; 277:402-6; PMID:11700328; http://dx.doi.org/10.1074/jbc. M110229200.
96. Fernandez LP, Milne RL, Pita G, Aviles JA, Lazaro P, Benitez J, et al. SLC45A2: a novel malignant melanoma-associated gene. Hum Mutat 2008; 29:1161-7; PMID:18563784; http://dx.doi.org/10.1002/ humu.20804.
97. Kobayashi T, Urabe K, Orlow SJ, Higashi K, Imokawa G, Kwon BS, et al. The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function. J Biol Chem 1994; 269:29198-205; PMID:7961886.
98. Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. Mol Biol Cell 2001; 12:3451-64; PMID:11694580.
99. Chakraborty AK, Platt JT, Kim KK, Kwon BS, Bennett DC, Pawelek JM. Polymerization of 5,6-dihydroxyindole-2-carboxylic acid to melanin by the pmel 17/silver locus protein. Eur J Biochem 1996; 236:180-8; PMID:8617263; http://dx.doi. org/10.1111/j.1432-1033.1996.t01-1-00180.x.
100. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003; 163:333-43; PMID:12819038; http://dx.doi. org/10.1016/S0002-9440(10)63657-7.
101. Guo H, Carlson JA, Slominski A. Role of TRPM in melanocytes and melanoma. Exp Dermatol 2012; 21:650-4; PMID:22897572; http://dx.doi. org/10.1111/j.1600- 0625.2012.01565.x.
102. Carlson JA, Ross JS, Slominski AJ. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol 2009; 27:75-102; PMID:19095155; http://dx.doi.org/10.1016/j.clindermatol. 2008.09.007.
103. Lu S, Slominski A, Yang S-E, Sheehan C, Ross J, Carlson JA. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesisrelated proteins in normal and pathological skin, hair follicles and melanocytic nevi. J Cutan Pathol 2010; 37(Suppl 1):26-40; PMID:20482673; http://dx.doi. org/10.1111/j.1600-0560.2010. 01504.x.
104. Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 2000; 31:1346-56; PMID:11112208; http://dx.doi. org/10.1016/S0046-8177(00)80003-9.
105. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE 2010; 5:e13779; PMID:21072171; http:// dx.doi.org/10.1371/journal.pone.0013779.
106. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010; 40:841-9; PMID:21109473; http://dx.doi. org/10.1016/j.molcel.2010.11.020.
107. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999; 885:312-28; PMID:10816663; http://dx.doi. org/10.1111/j.1749-6632.1999.tb08687.x.
108. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62; PMID:7715646; http://dx.doi. org/10.1056/NEJM199505183322008.
109. Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006; 27:260-86; PMID:16484629; http://dx.doi.org/10.1210/er.2005-0034.
110. Slominski A, Ermak G, Mazurkiewicz JE, Baker J, Wortsman J. Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab 1998; 83:1020-4; PMID:9506767; http:// dx.doi.org/10.1210/jc. 83.3.1020.
111. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol 2007; 265-266:143-9; PMID:17197073; http://dx.doi.org/10.1016/j. mce.2006.12.012.
112. Slominski A, Baker J, Ermak G, Chakraborty A, Pawelek J. Ultraviolet B stimulates production of corticotropin releasing factor (CRF) by human melanocytes. FEBS Lett 1996; 399:175-6; PMID:8980146; http:// dx.doi.org/10.1016/S0014-5793(96)01315-4.
113. Zbytek B, Wortsman J, Slominski A. Characterization of a ultraviolet B-induced corticotropin-releasing hormone-proopiomelanocortin system in human melanocytes. Mol Endocrinol 2006; 20:2539-47; PMID:16740657; http://dx.doi.org/10.1210/ me.2006-0116.
114. Skobowiat C, Dowdy JC, Sayre RM, Tuckey RC, Slominski AT. Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. Am J Physiol Endocrinol Metab 2011; 301:E484-93; PMID:21673307; http://dx.doi.org/10.1152/ajpendo. 00217.2011.
115. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol 2006; 206:780-91; PMID:16245303; http://dx.doi. org/10.1002/jcp.20530.
116. Zbytek B, Pfeffer LM, Slominski AT. CRH inhibits NF-kappa B signaling in human melanocytes. Peptides 2006; 27:3276-83; PMID:16959375; http://dx.doi. org/10.1016/j.peptides.2006.07.017.
117. Ito N, Ito T, Kromminga A, Bettermann A, Takigawa M, Kees F, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary- adrenal axis and synthesize cortisol. FASEB J 2005; 19:1332-4; PMID:15946990.
118. Slominski A. On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol 2009; 160:229-32; PMID:19187344; http://dx.doi.org/10.1111/ j.1365-2133.2008.08958.x.
119. Kauser S, Slominski A, Wei ET, Tobin DJ. Modulation of the human hair follicle pigmentary unit by corticotropin-releasing hormone and urocortin peptides. FASEB J 2006; 20:882-95; PMID:16675846; http:// dx.doi.org/10.1096/fj. 05-5257com.
120. Chen XQ, Du JZ, Wang YS. Regulation of hypoxiainduced release of corticotropin-releasing factor in the rat hypothalamus by norepinephrine. Regul Pept 2004; 119:221-8; PMID:15120484; http://dx.doi. org/10.1016/j.regpep.2004. 02.005.
121. Fan JM, Chen XQ, Jin H, Du JZ. Gestational hypoxia alone or combined with restraint sensitizes the hypothalamic-pituitary-adrenal axis and induces anxiety-like behavior in adult male rat offspring. Neuroscience 2009; 159:1363-73; PMID:19409200; http://dx.doi. org/10.1016/j.neuroscience.2009.02. 009.
122. Fassbender K, Schmidt R, Mossner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamicpituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 1994; 25:1105-8; PMID:8202965; http://dx.doi.org/10.1161/01.STR. 25.6.1105.
123. Allen LH. Biological mechanisms that might underlie iron's effects on fetal growth and preterm birth. J Nutr 2001; 131(2S-2):581S-9S; PMID:11160591.
124. Ito M, Kawa Y, Ono H, Okura M, Baba T, Kubota Y, et al. Removal of stem cell factor or addition of monoclonal anti-c-KIT antibody induces apoptosis in murine melanocyte precursors. J Invest Dermatol 1999; 112:796-801; PMID:10233774; http://dx.doi. org/10.1046/j.1523-1747.1999.00552.x.
125. Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol 1994; 103(Suppl):137S-40S; PMID:7525736; http://dx.doi.org/10.1038/ jid.1994.25.
126. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009; 24:643-50; PMID:19283671.
127. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 2010; 29:2938-49; PMID:20208561; http://dx.doi. org/10.1038/onc.2010.60.
128. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006; 5:1415-22; PMID:16818499; http://dx.doi.org/10.1158/1535-7163.MCT-05-0503.
129. Zhang H, Zhang G, Gonzalez FJ, Park SM, Cai D. Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol 2011; 9:e1001112; PMID:21814490; http://dx.doi.org/10. 1371/journal. pbio.1001112.
130. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010; 29:227-36; PMID:19802003; http://dx.doi. org/10.1038/onc.2009.320.
131. Tidyman WE, Rauen KA. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10:e37; PMID:19063751; http://dx.doi.org/10.1017/ S1462399408000902.
132. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. Am J Surg Pathol 2010; 34:1436-41; PMID:20871217; http://dx.doi.org/ 10.1097/ PAS.0b013e3181f0a749.
133. Jiang Y, Zheng W, Teegarden D. 1, 25-Dihydroxyvitamin D regulates hypoxia-inducible factor-1 in untransformed and Harvey-ras transfected breast epithelial cells. Cancer Lett 2010; 298:159-66; PMID:20655141; http://dx.doi.org/10.1016/j.canlet.2010.06.014.
134. Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol 2006; 126:1966-75; PMID:16912693; http://dx.doi. org/10.1038/sj.jid. 5700421.
135. Zhang H, Zhang G, Gonzalez FJ, Park SM, Cai D. Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol 2011; 9:e1001112; PMID:21814490; http://dx.doi.org/10. 1371/journal. pbio.1001112.
136. Choi JW, Park SC, Kang GH, Liu JO, Youn HD. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Res 2004; 64:35-9; PMID:14729605; http://dx.doi. org/10.1158/0008-5472.CAN-03-0145.
137. Lautenschlager NT, Milunsky A, DeStefano A, Farrer L, Baldwin CT. A novel mutation in the MITF gene causes Waardenburg syndrome type 2. Genet Anal 1996; 13:43-4; PMID:8880147; http://dx.doi. org/10.1016/1050-3862(95)00148-4.
138. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012; 31:2461-70; PMID:21996743; http://dx.doi.org/10.1038/onc.2011. 425.
139. Feige E, Yokoyama S, Levy C, Khaled M, Igras V, Lin RJ, et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci USA 2011; 108:E924-33; PMID:21949374; http://dx.doi.org/10.1073/pnas.1106351108.
140. Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res 2010; 23:496-513; PMID:20444197; http://dx.doi.org/10.1111/j.1755-148X.2010.00711.x.
141. Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Prehu MO, Puliti A, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 1998; 18:171-3; PMID:9462749; http://dx.doi. org/10.1038/ng0298-171.
142. Elworthy S, Lister JA, Carney TJ, Raible DW, Kelsh RN. Transcriptional regulation of mitfa accounts for the sox10 requirement in zebrafish melanophore development. Development 2003; 130:2809-18; PMID:12736222; http://dx.doi.org/10. 1242/ dev.00461.
143. Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell &. Melanoma Res 2009 22:435-44.
144. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012; 14:882-90; PMID:22772081;.
145. Robins JC, Akeno N, Mukherjee A, Dalal RR, Aronow BJ, Koopman P, et al. Hypoxia induces chondrocytespecific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. Bone 2005; 37:313-22; PMID:16023419; http://dx.doi. org/10.1016/j.bone.2005.04.040.
146. Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 2010; 465:577-83; PMID:20520707; http:// dx.doi.org/10.1038/nature09141.
147. Yaar M, Park HY. Melanocytes: a window into the nervous system. J Invest Dermatol 2012; 132:835-45; PMID:22158549; http://dx.doi.org/10.1038/ jid.2011.386.
148. Spinella F, Rosano L, Di Castro V, Decandia S, Nicotra MR, Natali PG, et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res 2007; 67:1725-34; PMID:17308114; http://dx.doi. org/10.1158/0008-5472.CAN-06-2606.
149. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012; 18:124-31; PMID:22453012; http://dx.doi. org/10.1097/PPO. 0b013e31824b436e.
150. Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC.-973. EJNMMI Res 2012; 2:22; PMID:22651703.
151. Yan N, Liao X, Cai SP, Lan C, Wang Y, Zhou X, et al. A novel nonsense mutation of the GPR143 gene identified in a Chinese pedigree with ocular albinism. PLoS ONE 2012; 7:e43177; PMID:22916221; http:// dx.doi.org/10.1371/ journal.pone.0043177.
152. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60:4873-80; PMID:10987301.
153. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21; PMID:7987387; http://dx.doi.org/10.1038/ng0994-15.
154. Zhang J, Lu A, Li L, Yue J, Lu Y. p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest 2010; 28:588-97; PMID:20307196; http://dx.doi. org/10.3109/07357900903286941.
155. Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, da Piedade I, et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res 2008; 36(Database issue):D102-6; PMID:18006571; http://dx.doi.org/10.1093/nar/gkm955.
156. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006; 34(Database issue):D108-10; PMID:16381825; http://dx.doi. org/10.1093/nar/gkj143.
157. Tonon L, Touzet H, Varre JS. TFM-Explorer: mining cis-regulatory regions in genomes. Nucleic Acids Res 2010; 38(Web Server issue):W286-92; PMID:20522509; http://dx.doi.org/10.1093/nar/ gkq473.